5. Utredning og diagnostikk

(2018). CT/MRI LI-RADS®v2018 CORE Reston, VA: American College of Radiology. Hentet fra https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf

Brierley, J., Gospodarowicz, M. K., Wittekind, C. (red.). (2017). TNM classification of malignant tumours. Wiley.

Burt, A. D., Alves, V., Bedossa, P., Clouston, A., Guido, M., Hubscher, S., Kakar, S., Ng, I., ... Ellis, D. W. (2018). Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 73(3), 369-385.

Burt, A. D., Alves, V., Clouston, A. D., Guido, M., Hübscher, S. G., Kakar, S., Ng, I. O., Nyun Park, Y., Washington, M. K. (November 2020). Intrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma and Hepatocellular Carcinoma Histopathology Reporting Guide. [dataset]. Sydney: International Collaboration on Cancer Reporting. Hentet 18. desember 2022 fra https://www.iccr-cancer.org/datasets/published-datasets/digestive-tract/liver/

Childs, A., Zakeri, N., Ma, Y. T., O'Rourke, J., Ross, P., Hashem, E., Hubner, R. A., Hockenhull, K., ... Meyer, T. (2021). Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit. British Journal of Cancer, 125(10), 1350-1355.

de Franchis, R., Bosch, J., Garcia-Tsao, G., Reiberger, T., Ripoll, C., & Baveno, V. I. I. F. (2022). Baveno VII - Renewing consensus in portal hypertension. Journal of Hepatology, 76(4), 959-974.

European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 69(1), 182-236.

European Association for the Study of the Liver, & Clinical Practice Guideline (2021). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. Journal of Hepatology, 75(3), 659-689.

Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., Kudo, M., Breder, V., ... Investigators, I. M. (2020). Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 382(20), 1894-1905.

Hanif, H., Ali, M. J., Susheela, A. T., Khan, I. W., Luna-Cuadros, M. A., Khan, M. M., & Lau, D. T. (2022). Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World Journal of Gastroenterology, 28(2), 216-229.

Johnson, P. J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H. L., O'Beirne, J., Fox, R., ... Toyoda, H. (2015). Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. Journal of Clinical Oncology, 33(6), 550-8.

Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, E. R., & Kim, W. R. (2001). A model to predict survival in patients with end-stage liver disease. Hepatology, 33(2), 464-70.

Kielar, A. Z., Elsayes, K. M., Chernyak, V., Tang, A., & Sirlin, C. B. (2019). LI-RADS version 2018: What is new and what does this mean to my radiology reports?. Abdominal radiology (New York), 44(1), 41-42.

Lencioni, R., & Llovet, J. M. (2010). Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in Liver Disease, 30(1), 52-60.

Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., ... Finn, R. S. (2021). Hepatocellular carcinoma. Nature reviews. Disease primers, 7(1), 6.

Llovet, J. M., & Lencioni, R. (2020). mRECIST for HCC: Performance and novel refinements. Journal of Hepatology, 72(2), 288-306.

Mazzaferro, V., Sposito, C., Zhou, J., Pinna, A. D., De Carlis, L., Fan, J., Cescon, M., Di Sandro, S., ... Cucchetti, A. (2018). Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology, 154(1), 128-139.

Neuberger, J., Patel, J., Caldwell, H., Davies, S., Hebditch, V., Hollywood, C., Hubscher, S., Karkhanis, S., ... Heydtmann, M. (2020). Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology. Gut, 69(8), 1382-1403.

Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973). Transection of the oesophagus for bleeding oesophageal varices. British Journal of Surgery, 60(8), 646-9.

Reig, M., Forner, A., Rimola, J., Ferrer-Fabrega, J., Burrel, M., Garcia-Criado, A., Kelley, R. K., Galle, P. R., ... Bruix, J. (2022). BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology, 76(3), 681-693.

Salgia, R., & Mendiratta, V. (2021). The Multidisciplinary Management of Hepatocellular Carcinoma. Clinical liver disease, 17(6), 405-408.

Torbenson, M. S. (2021). Hepatocellular carcinoma: making sense of morphological heterogeneity, growth patterns, and subtypes. Human Pathology, 112, 86-101.

Vernuccio, F., Porrello, G., Cannella, R., Vernuccio, L., Midiri, M., Giannitrapani, L., Soresi, M., & Brancatelli, G. (2021). Benign and malignant mimickers of infiltrative hepatocellular carcinoma: tips and tricks for differential diagnosis on CT and MRI. Clinical Imaging, 70, 33-45.

Welle, C. L., Guglielmo, F. F., & Venkatesh, S. K. (2020). MRI of the liver: choosing the right contrast agent. Abdominal radiology (New York), 45(2), 384-392.

Wu, H., Xing, H., Liang, L., Huang, B., Li, C., Lau, W. Y., Zhou, Y. H., Gu, W. M., ... Yang, T. (2019). Real-world role of performance status in surgical resection for hepatocellular carcinoma: A multicenter study. European Journal of Surgical Oncology, 45(12), 2360-2368.

Wyatt, J., Hübscher, S., Goldin, R., Tiniakos, D. (Oktober 2020). G064 Tissue pathways for liver biopsies for the investigation of medical disease and focal lesions For Publication. [dataset]. London: Royal College of Pathologists. Hentet 18. desember 2022 fra https://www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html

Wyatt, J., Hübscher, S., Goldin, R., Tiniakos, D. (September 2022). G050 Dataset for histopathological reporting of liver resection specimens (including gallbladder) and liver biopsies for primary and metastatic carcinoma. [dataset]. London: Royal College of Pathologists. Hentet 2022 fra https://www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html

Yau, T., Tang, V. Y., Yao, T. J., Fan, S. T., Lo, C. M., & Poon, R. T. (2014). Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology, 146(7), 1691-700 e3.

Yoshiji, H., Nagoshi, S., Akahane, T., Asaoka, Y., Ueno, Y., Ogawa, K., Kawaguchi, T., Kurosaki, M., ... Koike, K. (2021). Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. Journal of Gastroenterology, 56(7), 593-619.